PL1909830T3 - Ograniczenie oddziaływania pomiędzy olejem w adiuwancie a środkiem powierzchniowo czynnym w antygenie - Google Patents

Ograniczenie oddziaływania pomiędzy olejem w adiuwancie a środkiem powierzchniowo czynnym w antygenie

Info

Publication number
PL1909830T3
PL1909830T3 PL06795518T PL06795518T PL1909830T3 PL 1909830 T3 PL1909830 T3 PL 1909830T3 PL 06795518 T PL06795518 T PL 06795518T PL 06795518 T PL06795518 T PL 06795518T PL 1909830 T3 PL1909830 T3 PL 1909830T3
Authority
PL
Poland
Prior art keywords
surfactant
oil
reducing interference
adjuvants
antigens
Prior art date
Application number
PL06795518T
Other languages
English (en)
Inventor
Mario Contorni
Original Assignee
Novartis Vaccines And Diagnostics S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37684892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1909830(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0515906.6A external-priority patent/GB0515906D0/en
Priority claimed from GB0522599A external-priority patent/GB0522599D0/en
Priority claimed from GB0523923A external-priority patent/GB0523923D0/en
Application filed by Novartis Vaccines And Diagnostics S R L filed Critical Novartis Vaccines And Diagnostics S R L
Publication of PL1909830T3 publication Critical patent/PL1909830T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
PL06795518T 2005-08-02 2006-08-02 Ograniczenie oddziaływania pomiędzy olejem w adiuwancie a środkiem powierzchniowo czynnym w antygenie PL1909830T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB0515906.6A GB0515906D0 (en) 2005-08-02 2005-08-02 Mixtures of antigen and adjuvant
GB0522599A GB0522599D0 (en) 2005-11-04 2005-11-04 Adjuvants and antigens
GB0523923A GB0523923D0 (en) 2005-11-24 2005-11-24 Adjuvants and antigens
EP06795518A EP1909830B1 (en) 2005-08-02 2006-08-02 Reducing interference between oil-containing adjuvants and surfactant-containing antigens
PCT/IB2006/002581 WO2007015167A2 (en) 2005-08-02 2006-08-02 Reducing interference between oil-containing adjuvants and surfactant-containing antigens

Publications (1)

Publication Number Publication Date
PL1909830T3 true PL1909830T3 (pl) 2012-02-29

Family

ID=37684892

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06795518T PL1909830T3 (pl) 2005-08-02 2006-08-02 Ograniczenie oddziaływania pomiędzy olejem w adiuwancie a środkiem powierzchniowo czynnym w antygenie

Country Status (21)

Country Link
US (1) US20090220547A1 (pl)
EP (1) EP1909830B1 (pl)
JP (1) JP2009503051A (pl)
KR (1) KR101321732B1 (pl)
CN (1) CN103690945A (pl)
AP (1) AP2745A (pl)
AT (1) ATE526036T1 (pl)
AU (1) AU2006274647B2 (pl)
BR (1) BRPI0614254A2 (pl)
CA (1) CA2617362A1 (pl)
CY (1) CY1112149T1 (pl)
DK (1) DK1909830T3 (pl)
EA (1) EA014314B1 (pl)
IL (1) IL189102A (pl)
MX (1) MX2008001527A (pl)
NO (1) NO20081033L (pl)
NZ (1) NZ565512A (pl)
PL (1) PL1909830T3 (pl)
PT (1) PT1909830E (pl)
SI (1) SI1909830T1 (pl)
WO (1) WO2007015167A2 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2366941T3 (es) 2008-08-28 2011-10-26 Novartis Ag Producción de escualeno a partir de levaduras hiperproductoras.
ES2731636T3 (es) * 2011-03-11 2019-11-18 Km Biologics Co Ltd Composición adyuvante que contiene citrulina
FR3002454B1 (fr) * 2013-02-26 2015-04-10 Commissariat Energie Atomique Composition immunogene sous forme d'emulsion
US9968673B2 (en) 2013-02-26 2018-05-15 Commissariat á l'ènergie atomique et aux ènergies alternatives Immunogenic composition in emulsion form comprising two dispersed phases, one comprising an antigen and the other comprising an immunostimulating agent
FR3043558B1 (fr) * 2015-11-18 2017-12-29 Commissariat Energie Atomique Composition immunogene sous forme d'emulsion comprenant deux phases dispersees, l'une comprenant un antigene et l'autre comprenant un agent immunostimulant
WO2017085248A1 (fr) * 2015-11-18 2017-05-26 Commissariat à l'énergie atomique et aux énergies alternatives Composition immunogène sous forme d'émulsion comprenant deux phases dispersées, l'une comprenant un antigène et l'autre comprenant un agent immunostimulant
TWI827732B (zh) * 2018-12-24 2024-01-01 大陸商遠大賽威信生命科學（南京）有限公司 用於治療b型肝炎的藥物製劑及其製備方法和用途
TW202245835A (zh) * 2021-02-04 2022-12-01 美商默沙東有限責任公司 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3435112A (en) * 1966-06-21 1969-03-25 Norden Lab Inc Repository vaccine and method of preparing the same
US4199565A (en) * 1979-03-26 1980-04-22 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4683294A (en) * 1985-04-03 1987-07-28 Smith Kline Rit, S.A. Process for the extraction and purification of proteins from culture media producing them
US4649192A (en) * 1985-05-30 1987-03-10 Smith Kline-Rit Method for the isolation and purification of hepatitis B surface antigen using polysorbate
CA2017507C (en) * 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
US5709879A (en) * 1990-06-29 1998-01-20 Chiron Corporation Vaccine compositions containing liposomes
GB9503863D0 (en) * 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
US5718904A (en) * 1995-06-02 1998-02-17 American Home Products Corporation Adjuvants for viral vaccines
DE69636889T2 (de) * 1995-11-30 2007-12-06 Nof Corp. Öladjuvierter Impfstoff und Verfahren zu seiner Herstellung
GB9616351D0 (en) * 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
ATE278419T1 (de) * 1997-04-01 2004-10-15 Corixa Corp Wässerige immunologische adjuvantzusammensetzungen aus monophosphoryllipid a
GB9718901D0 (en) * 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
IL140890A0 (en) * 1998-07-14 2002-02-10 American Cyanamid Co Adjuvant and vaccine compositions containing monophosphoryl lipid a
DK1126876T3 (da) * 1998-10-16 2007-07-02 Glaxosmithkline Biolog Sa Adjuvanssystemer og vacciner
TR200103018T2 (tr) * 1999-04-19 2002-02-21 Beecham Biologicals S.A. Smithkline İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri.
WO2001021151A1 (en) * 1999-09-24 2001-03-29 Smithkline Beecham Biologicals S.A. Intranasal influenza virus vaccine
JP2001151699A (ja) * 1999-11-29 2001-06-05 Nippon Surfactant Kogyo Kk 動物用ワクチンのオイルアジュバント
KR20010105882A (ko) * 2000-05-19 2001-11-29 배길훈 스티어링 칼럼 구조
UA79735C2 (uk) * 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
US6753015B2 (en) * 2000-09-28 2004-06-22 Chiron Corporation Microparticle compositions and methods for the manufacture thereof
EP1256804B1 (en) * 2001-05-09 2012-09-26 Bio Merieux HBcAg expression and diagnostic and therapeutic uses
MY134424A (en) * 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
US20090214592A1 (en) * 2005-02-16 2009-08-27 O'hagan Derek Adjuvant composition comprising aluminium phosphate and 3D-MPL
WO2006113528A2 (en) * 2005-04-18 2006-10-26 Novartis Vaccines And Diagnostics Inc. Expressing hepatitis b virus surface antigen for vaccine preparation

Also Published As

Publication number Publication date
ATE526036T1 (de) 2011-10-15
AU2006274647A1 (en) 2007-02-08
IL189102A0 (en) 2008-08-07
AU2006274647B2 (en) 2013-01-10
IL189102A (en) 2011-09-27
KR20080038384A (ko) 2008-05-06
BRPI0614254A2 (pt) 2011-03-15
EP1909830B1 (en) 2011-09-28
AP2745A (en) 2013-09-30
EA014314B1 (ru) 2010-10-29
CA2617362A1 (en) 2007-02-08
CY1112149T1 (el) 2015-11-04
WO2007015167A2 (en) 2007-02-08
EA200800509A1 (ru) 2008-10-30
NO20081033L (no) 2008-02-27
JP2009503051A (ja) 2009-01-29
SI1909830T1 (sl) 2012-01-31
EP1909830A2 (en) 2008-04-16
WO2007015167A3 (en) 2007-05-03
CN103690945A (zh) 2014-04-02
MX2008001527A (es) 2008-04-04
NZ565512A (en) 2011-08-26
KR101321732B1 (ko) 2013-10-29
US20090220547A1 (en) 2009-09-03
DK1909830T3 (da) 2011-12-19
PT1909830E (pt) 2011-11-24

Similar Documents

Publication Publication Date Title
IL222922A (en) Antibodies against neurophilin-1 and their use
PT1599504E (pt) Anticorpo modificado
LT2913343T (lt) Anti-ilt7 antikūnas
IL189102A0 (en) Reducing interference between oil-containing adjuvants and surfactant- containing antigens
IL192119A0 (en) Novel cancer -associated antigen
GB0503546D0 (en) Antibody
AP2191A (en) Methods of reducing nematode damage.
IL185781A0 (en) Antibodies against candida antigens
GB0502298D0 (en) Well assembly and method
GB0329178D0 (en) Surfactant
EP1806121A4 (en) PREPARATION AGAINST TRUST
GB2428042B (en) P gingivalis vaccine
IL215527A (en) Methods will notice training
ZA200801004B (en) Reducing interference between oil-containing adjuvants and surfactant-containing antigens
ZA200707838B (en) Antibodies against Candida antigens
EP1780221A4 (en) ANTI-SYNOVIOLIN ANTIBODY
EP1820615A4 (en) MECHANICAL RABOT
GB0418444D0 (en) Montage method
AP2007004280A0 (en) Immunological adjuvant emulsion
GB0507672D0 (en) Adjuvant
GB0522599D0 (en) Adjuvants and antigens
GB0523923D0 (en) Adjuvants and antigens
GB0420771D0 (en) Antibody
GB0404725D0 (en) Tmt
AU2004904522A0 (en) Gyp stay